{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:41:19Z","timestamp":1790710879747,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Kowa Company, Ltd, Nagoya, Japan"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the intra\u2010ocular pressure (<jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>)\u2010lowering effects and safety of 0.4% ripasudil (K\u2010115), a Rho kinase inhibitor, twice daily for 52\u00a0weeks, in patients with open\u2010angle glaucoma or ocular hypertension (<jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicentre, prospective, open\u2010label study, 388 patients with primary open\u2010angle glaucoma, <jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content> or exfoliation glaucoma were enrolled and 354 of them were subdivided into four cohorts (monotherapy, 173; additive therapy to prostaglandin analogs, 62; <jats:italic>\u03b2<\/jats:italic>\u2010blockers, 60; or fixed combination drugs, 59). The <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> reduction at trough and peak from baseline and adverse events was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ripasudil showed <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>\u2010lowering effects over 52\u00a0weeks in all the analyses of monotherapy, additive therapy and both subgroups (baseline <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> \u226521\u00a0mmHg and &lt;21\u00a0mmHg) of monotherapy. The mean <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> reductions at trough and peak at week 52 were \u22122.6 and \u22123.7\u00a0mmHg for monotherapy, and \u22121.4 and \u22122.4, \u22122.2 and \u22123.0, and \u22121.7 and \u22121.7\u00a0mmHg, respectively, for additive therapy described above. The most frequently observed adverse events were conjunctival hyperaemia (<jats:italic>n<\/jats:italic>\u00a0=\u00a0264, 74.6%), blepharitis (<jats:italic>n<\/jats:italic>\u00a0=\u00a073, 20.6%) and allergic conjunctivitis (<jats:italic>n<\/jats:italic>\u00a0=\u00a061, 17.2%). Most of the conjunctival hyperaemia findings were mild (97.0%), transient and resolved spontaneously (78.0%). Although 51 patients discontinued from the study due to blepharitis and\/or allergic conjunctivitis (blepharitis, 28; allergic conjunctivitis, 17; both, 6), all the events resolved with or without treatment after the discontinuation of ripasudil administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fifty\u2010two week administration of 0.4% ripasudil revealed <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>\u2010lowering effects and an acceptable safety profile when administered as monotherapy or as additive therapy, in patients with open\u2010angle glaucoma or <jats:styled-content style=\"fixed-case\">OHT<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.12829","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T08:42:19Z","timestamp":1441356139000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["One\u2010year clinical evaluation of 0.4% ripasudil (K\u2010115) in patients with open\u2010angle glaucoma and ocular hypertension"],"prefix":"10.1111","volume":"94","author":[{"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Faculty of Life Sciences Kumamoto University Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Faculty of Life Sciences Kumamoto University Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Gifu University Graduate School of Medicine Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[{"name":"Fukushima Eye Clinic Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Abe","sequence":"additional","affiliation":[{"name":"Niigata University of Health and Welfare Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science Kochi Medical School Kochi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[{"name":"Kowa Company Ltd Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Araie","sequence":"additional","affiliation":[{"name":"Kanto Central Hospital of the Mutual Aid Association of Public School Teachers Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the K\u2010115 Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1998.171"},{"key":"e_1_2_5_3_1","first-page":"137","article-title":"Effects of rho\u2010associated protein kinase inhibitor Y\u201027632 on intraocular pressure and outflow facility","volume":"42","author":"Honjo M","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_4_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use(1994):ICH Harmonised Tripartite Guideline: the extent of population exposure to assess clinical safety for drugs intended for long\u2010term treatment of non\u2010life\u2010threatening conditions E1. Available at:http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E1\/Step4\/E1_Guideline.pdf. Accessed Dec 15 2014."},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2013.874444"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8018"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.20"},{"key":"e_1_2_5_8_1","first-page":"495","article-title":"Double\u2010masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride\/0.5% timolol maleate (MK\u20100507A) in patients with glaucoma and ocular hypertension","volume":"115","author":"Kitazawa Y","year":"2011","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.09.026"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2131\/fts.1.19"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00450-4"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.76"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.016"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.323"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.0525"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.131"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1617"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/40187"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200006000-00006"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.04.012"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2012.11.595"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.12829","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.12829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:43:21Z","timestamp":1695516201000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.12829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/aos.12829"],"URL":"https:\/\/doi.org\/10.1111\/aos.12829","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]},"assertion":[{"value":"2015-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}